{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:26:46Z","timestamp":1792603606562,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["1.5 CUP B83C22003920001"],"award-info":[{"award-number":["1.5 CUP B83C22003920001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118992","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:23:40Z","timestamp":1779319420000},"page":"118992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Multivalent C2-alkyl trihydroxypiperidine architectures modulate \u03b2-glucocerebrosidase activity"],"prefix":"10.1016","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1200-1935","authenticated-orcid":false,"given":"Francesca","family":"Buco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-4624","authenticated-orcid":false,"given":"Francesca","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-8179","authenticated-orcid":false,"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-7266","authenticated-orcid":false,"given":"Paolo","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7174-1960","authenticated-orcid":false,"given":"Sergio E.","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-533X","authenticated-orcid":false,"given":"Andrea","family":"Goti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-383X","authenticated-orcid":false,"given":"Camilla","family":"Matassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-6942","authenticated-orcid":false,"given":"Marco","family":"Marradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118992_bib1","series-title":"Advances in Gaucher Disease: Basic and Clinical Perspectives","author":"Grabowski","year":"2013"},{"key":"10.1016\/j.ejmech.2026.118992_bib2","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.3390\/diagnostics14242840","article-title":"An overview of gaucher disease","volume":"14","author":"M\u00e9ndez-Cobi\u00e1n","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejmech.2026.118992_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2026.118992_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118992_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cells11081261","article-title":"GBA variants and parkinson disease: mechanisms and treatments","volume":"11","author":"Smith","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.118992_bib6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/genes15121605","article-title":"A global perspective of GBA1-Related parkinson's disease: a narrative review","volume":"15","author":"Koros","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2026.118992_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1671760","article-title":"Effects of glucocerebrosidase gene variations on the risk of Parkinson's disease dementia: a meta-analysis","volume":"17","author":"Li","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2026.118992_bib8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-Butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118992_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","article-title":"Low-dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease","volume":"28","author":"Heitner","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejmech.2026.118992_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.118992_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2026.118992_bib12","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib13","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.3390\/ijms23073536","article-title":"Mechanistic insight into the mode of action of acid \u03b2-Glucosidase enhancer ambroxol","volume":"23","author":"Pantoom","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118992_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejmech.2026.118992_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2026.118992_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108556","article-title":"Clinical and preclinical insights into high-dose ambroxol therapy for gaucher disease type 2 and 3: a comprehensive systematic review","volume":"143","author":"den Hollander","year":"2024","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2026.118992_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-024-03629-9","article-title":"Study protocol of the GRoningen Early-PD ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled single-centre trial with ambroxol in parkinson patients with a GBA mutation","volume":"24","author":"Siemeling","year":"2024","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejmech.2026.118992_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687","article-title":"Ambroxol as a treatment for parkinson disease dementia: a randomized clinical trial","volume":"82","author":"Silveira","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2026.118992_bib19","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from gaucher, GM1-Gangliosidosis and fabry diseases","volume":"52","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118992_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/ph15070823","article-title":"GCase enhancers: a potential therapeutic option for gaucher disease and other neurological disorders","volume":"15","author":"Mart\u00ednez-Bail\u00e9n","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118992_bib21","series-title":"Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera\u2122 for Gaucher Disease","year":"2009"},{"key":"10.1016\/j.ejmech.2026.118992_bib22","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1002\/anie.200502662","article-title":"Rational design and synthesis of highly potent \u03b2-Glucocerebrosidase inhibitors","volume":"44","author":"Zhu","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118992_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/cbic.200600217","article-title":"Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease","volume":"7","author":"Compain","year":"2006","journal-title":"ChemBioChem"},{"issue":"741","key":"10.1016\/j.ejmech.2026.118992_bib24","first-page":"340","article-title":"Hydroxy piperidine derivatives to treat gaucher disease","volume":"7","author":"Fan","year":"2010","journal-title":"U.S. Patent"},{"key":"10.1016\/j.ejmech.2026.118992_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1039\/C5OB02223A","article-title":"Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for gaucher disease","volume":"14","author":"Kato","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/acsmedchemlett.8b00602","article-title":"Stereoselective synthesis of C-2 alkylated trihydroxypiperidines: novel pharmacological chaperones for gaucher disease","volume":"10","author":"Clemente","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118992_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103740","article-title":"Glucocerebrosidase (GCase) activity modulation by 2-Alkyl trihydroxypiperidines: inhibition and pharmacological chaperoning","volume":"98","author":"Clemente","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib28","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1039\/D0OB01522A","article-title":"Concise asymmetric synthesis of new enantiomeric C-Alkyl pyrrolidines acting as pharmacological chaperones against gaucher disease","volume":"18","author":"Castellan","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cbic.201200005","article-title":"Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders","volume":"13","author":"Decroocq","year":"2012","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2026.118992_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/cbic.201300442","article-title":"A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of gaucher disease","volume":"15","author":"Joosten","year":"2014","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2026.118992_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.carres.2016.03.007","article-title":"Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of gaucher disease","volume":"429","author":"Laigre","year":"2016","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2026.118992_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200077","volume":"23","author":"Vanni","year":"2022","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2026.118992_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202301210","article-title":"Phosphorus dendrimers for metal-free ligation: design of multivalent pharmacological chaperones against gaucher disease","volume":"29","author":"Tran","year":"2023","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2026.118992_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1021\/acs.bioconjchem.4c00496","article-title":"Multivalent GCase enhancers: synthesis and evaluation of glyco-gold nanoparticles decorated with trihydroxypiperidine iminosugars","volume":"36","author":"Buco","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib35","series-title":"Synthetic Multivalent Molecules: Concepts and Biomedical Applications","author":"Choi","year":"2004"},{"key":"10.1016\/j.ejmech.2026.118992_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107295","article-title":"Multivalent pyrrolidines acting as pharmacological chaperones against gaucher disease","volume":"146","author":"Borie-Guichot","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib37","doi-asserted-by":"crossref","first-page":"9121","DOI":"10.1039\/C7OB01848G","article-title":"Accessing 2-Substituted piperidine iminosugars by organometallic addition\/intramolecular reductive amination: Aldehyde vs. nitrone route","volume":"15","author":"Mirabella","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib38","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1055\/s-0036-1588457","article-title":"On the oxidation of hydroxylamines with o-Iodoxybenzoic acid (IBX)","volume":"49","author":"Parmeggiani","year":"2017","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2026.118992_bib39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1248\/cpb.c19-00209","article-title":"Total synthesis of 3-epi-Juruenolide C","volume":"67","author":"Kutsumura","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2026.118992_bib40","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1039\/C6OB00720A","article-title":"First total synthesis of (+)-Broussonetine W: glycosidase inhibition of natural product and analogs","volume":"14","author":"Song","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib41","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1002\/ejoc.201200587","article-title":"Double reductive amination and selective strecker reaction of a D-Lyxaric aldehyde: synthesis of diversely functionalized 3,4,5-Trihydroxypiperidines","volume":"2012","author":"Matassini","year":"2012","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib42","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1021\/jo8008935","article-title":"Expeditive synthesis of glycodendrimer scaffolds based on versatile TRIS and mannoside derivatives","volume":"73","author":"Chabre","year":"2008","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib43","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cbic.201000718","article-title":"Multivalent presentation of mannose on hyperbranched polyglycerol and their interaction with concanavalin A lectin","volume":"12","author":"Papp","year":"2011","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2026.118992_bib44","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1039\/C5OB01405K","article-title":"Emerging trends in enzyme inhibition by multivalent nanoconstructs","volume":"13","author":"Kanfar","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib45","doi-asserted-by":"crossref","first-page":"95817","DOI":"10.1039\/C5RA22152H","article-title":"Gold nanoparticles are suitable cores for building tunable iminosugar multivalency","volume":"5","author":"Matassini","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.118992_bib46","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/1521-3773(20010618)40:12<2257::AID-ANIE2257>3.0.CO;2-S","article-title":"Gold glyconanoparticles as water-soluble polyvalent models to study carbohydrate interactions","volume":"40","author":"de la Fuente","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118992_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1039\/C39940000801","article-title":"Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid\u2013liquid system","author":"Brust","year":"1994","journal-title":"J. Chem. Soc. Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118992_bib48","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1039\/D3OB01466E","article-title":"Gold nanoparticles decorated with monosaccharides and sulfated ligands as potential modulators of the lysosomal enzyme N-Acetylgalactosamine-6-Sulfatase (GALNS)","volume":"21","author":"Buco","year":"2023","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13240","article-title":"Evolution from the plasmon to exciton state in ligand-protected atomically precise gold nanoparticles","volume":"7","author":"Zhou","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118992_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1021\/la970588w","article-title":"Alkanethiolate gold cluster molecules with core diameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size","volume":"14","author":"Hostetler","year":"1998","journal-title":"Langmuir"},{"key":"10.1016\/j.ejmech.2026.118992_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s42004-024-01164-9","article-title":"A practical synthesis of nitrone-derived C5a-functionalized isofagomines as protein stabilizers to treat Gaucher disease","volume":"7","author":"Li","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117529","article-title":"Acetal functionalized iminosugars for targeting \u03b2-Glucocerebrosidase modulation","volume":"290","author":"Davighi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118453","article-title":"Selenoureido-N-alkyl-3,4,5-trihydroxypiperidines: probing their dual-Target role in gaucher disease","volume":"132","author":"Pratesi","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118992_bib54","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118992_bib55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luana","year":"2013","journal-title":"Brain Dev."},{"key":"10.1016\/j.ejmech.2026.118992_bib56","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acschemneuro.4c00618","article-title":"Evidence of \u03b1-Synuclein\/Glucocerebrosidase dual targeting by iminosugar derivatives","volume":"16","author":"Tagliaferro","year":"2025","journal-title":"ACS Chem. Neurosci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600437X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600437X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:16:54Z","timestamp":1783923414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600437X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"alternative-id":["S022352342600437X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118992","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent C2-alkyl trihydroxypiperidine architectures modulate \u03b2-glucocerebrosidase activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118992"}}